How to Handle Inconsistent Quality System Certificates for Overseas Registration of Rehabilitation Devices?

Published: 2026-08-17 18:23 | Updated: 2026-08-17 18:23

When an overseas registration for a rehabilitation device is affected by inconsistencies in quality system certificates, the core issue is the difference between the certificate's scope, standard version, issuing body recognition, and the target country's regulatory requirements. Companies should first confirm whether the product is regulated as a medical device in the target market, determine its risk class and registration pathway, and then systematically compare existing ISO 13485, NMPA system certification, CE/FDA system evidence, and other relevant documents against local requirements to assess whether the certificate covers the declared product, manufacturing site, and standard version. If inconsistencies are found, companies should supplement the quality system documentation, perform localised adaptations, and communicate with the regulatory authority through a local agent or authorised representative. In parallel, technical documentation, performance verification, risk management, clinical evaluation, labelling, and post-market maintenance files should be prepared to avoid requests for amendment or rejection. Common risks include expired certificates, failure to cover new products, unreported address changes, and mismatched standard versions. For Chinese medical device companies, a reliable approach is to first conduct product classification and documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Overseas registration typically affects technical documentation, authorised representatives, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If the project is driven only by a 'submission checklist' approach, manufacturers may face amendments or rework related to model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies plan this issue within the GHWP member countries and multi-market access strategy, using a set of reusable core technical files to support localisation in different markets rather than recreating documents for each country. This article is compiled based on AIMEILI's registration practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation baseline.

Applicable Scenarios and Core Issues

During overseas registration of rehabilitation devices, an inconsistency in quality system certificates means that the company's quality system certificate differs from the target country's regulatory requirements. Common situations include: the ISO 13485 certificate scope does not include the declared rehabilitation product; the production address on the certificate does not match the actual manufacturing site; the standard version referenced by the certificate is different from the version accepted by the target country; or the certificate was issued by an organisation not recognised by the target country.

This inconsistency is very common in GHWP member countries, Southeast Asia, the Middle East, Latin America, and other regions. Regulators usually treat quality system certificates as a required element for registration review. If a discrepancy is identified, the application may be subject to amendment at best or rejection at worst, which can delay product launch.

This article is intended for rehabilitation device manufacturers, CROs, and overseas business leaders to help them understand how to judge, prepare for, and resolve inconsistencies in quality system certificates.

Registration Determination Logic

Step 1: Confirm whether the product falls within the target country's medical device regulatory scope. Some rehabilitation devices, such as ordinary fitness resistance bands and massage chairs, may not be regulated as medical devices, while traction beds and neuromuscular electrical stimulators used for therapy are generally considered medical devices.

Step 2: Determine the product's risk class and registration pathway. Rehabilitation devices may be classified as Class A/B/C or Class I/II/III, and different classes correspond to different regulatory requirements and review methods. Quality system certificates are generally required for products above Class I.

Step 3: Assess the reusability of existing evidence. The company's NMPA production licence, ISO 13485 certificate, CE system certification, FDA Quality System Regulation (QSR 820) audit reports, MDSAP audit reports, and other evidence are important baseline documents, but their recognition varies by country.

Step 4: Conduct an item-by-item comparison of the target country's specific requirements for quality system certificates. Key checks include whether the issuing body is recognised, whether the certificate's validity period covers the registration submission period, whether the product category and code on the certificate include this product, whether the production address on the certificate matches the registration dossier, and whether the standard version referenced in the certificate is the latest and accepted by the target country.

Step 5: Determine the response based on the type of discrepancy. If it is a standard version difference, a difference declaration can be added or the system can be updated according to the target country's requirements. If the certificate scope does not cover the product, the certification body must be contacted to expand the scope or issue a new certificate. If the issuing body is not recognised, it may be necessary to have the system audited by a locally recognised body or provide other equivalent evidence.

Finally, select the registration pathway based on the product category. For example, in some Southeast Asian countries, Class B and above may require local testing and GMP audits; in the Middle East, countries such as the UAE may accept ISO 13485 plus a declaration of conformity; in Latin America, Brazil may require a local ANVISA audit. The CE pathway cannot simply be copied.

Documentation and Evidence

When quality system certificates are inconsistent, companies should not submit only a single certificate but should prepare a complete evidence package. This usually includes the full text of the quality system certificate (including attachments and scope pages), all previous audit reports, nonconformity closure records, online verification screenshots or official confirmation letters for certificate validity.

In addition, companies should prepare a description of the quality system documentation structure, including the quality manual, procedures, and control procedures related to this product, especially risk management, design control, production control, and corrective and preventive action sections. If the target country requires it, translated versions of quality system documents should also be provided.

If the existing system certificate partially overlaps with the declared product but does not explicitly cover it, the company can provide evidence of registration submissions for similar products to demonstrate that the system control scope substantively covers the product, and attach a confirmation letter from the certification body or supplementary audit records.

For production address mismatches, the company should provide the business licence, production licence, address change documents, and the relevant regulatory authority's filing or approval certificates. If the manufacturing site does not yet hold a quality system certificate recognised by the target country, an application for a local audit may be required.

In multi-country registration scenarios, a STED (Summary Technical Documentation) structure can be established, and quality system certificates can be managed as common documents. By integrating ISO 13485 certificates, MDSAP reports, and regulatory audit records from various countries, a coverage matrix can be produced to reduce repeated submission and discrepancy challenges.

In addition to system certificates, companies should also prepare product performance verification data, risk management reports (ISO 14971), clinical evaluation or clinical trial data, label and instruction leaflet drafts, and intended-use and indication descriptions. These materials can help corroborate the effectiveness of the system output and build confidence with regulators.

Ensure that the registrant and manufacturer names on all documents are consistent and use the same unique identifiers to avoid inconsistencies caused by spelling differences in company names.

Common Errors

• Submitting without checking the certificate scope. For example, using an ISO 13485 certificate that only covers 'physiotherapy equipment' for a 'rehabilitation robot' registration, which is then flagged by the review authority as a scope mismatch.
• Using an outdated standard version, such as ISO 13485:2003 instead of the target country's accepted ISO 13485:2016.
• Ignoring administrative changes to the production address. For example, moving from location A to location B while the certificate still shows the old address, but the registration dossier uses the new address, breaking the evidence chain.
• Treating CE certificates or FDA registration as globally accepted evidence without investigating whether the target country accepts third-party certification or requires local audits.
• Failing to confirm whether the issuing body is recognised by the target country. For example, using a certificate from a small certification body for entry into Saudi Arabia, while the Saudi SFDA only recognises specific bodies.
• Neglecting post-market change obligations. When significant product technology changes occur, the system certificate scope is not updated and the change is not declared in the target country.
• Failing to retain audit records and nonconformity closure evidence, leading regulators to question the continued effectiveness of the system.

Enterprise Preparation Checklist

• List the target countries and check each regulator's specific requirements for quality system certificates.
• Confirm the product's risk class and registration pathway, and determine whether clinical evaluation or clinical trials are needed.
• Retrieve all existing quality system certificates, including ISO 13485, MDSAP, CE, and FDA, and check validity, scope, standard version, and issuing body.
• Compare the list of nationally recognised bodies; if there is a gap, contact the relevant certification body as early as possible to arrange scope expansion or recertification.
• Review the consistency of information such as production address and legal representative name with the registration dossier, and complete change filings if necessary.
• Prepare a quality system gap analysis report that explains item by item how the target country's requirements will be met, supported by objective evidence.
• When preparing product technical documentation, associate the system certificate with the specific product to avoid a 'generic certificate' that cannot correspond to the declared product.
• Confirm with the partner agent or authorised representative the process for handling such issues to ensure a fast response to regulatory amendments.
• Establish a multi-country registration document library that centrally manages certificates, audit reports, and change records, keeping all market versions in sync.
• Conduct an internal mock pre-review before submission to resolve potential issues in advance.

AIMEILI's Perspective

The most common misjudgment is the belief that holding an ISO 13485 certificate ensures smooth market access globally. In reality, the applicability of a quality system certificate depends on whether the target country recognises the certificate and whether the certificate strictly matches the product, the site, and the standard version. Rehabilitation devices cover a wide range of categories with significant risk differences, and regulatory requirements vary greatly.

In the early phase of a project, companies should prioritise a multi-country registration gap analysis rather than waiting for an amendment after submission. A low-cost effort can identify certificate gaps and key risks, providing a basis for subsequent decisions.

Which materials can be reused? ISO 13485 certificates, MDSAP reports, NMPA system certification records, and risk management documents based on ISO 14971 can usually serve as common baseline evidence. However, they must be localised, for example, translated into the target country language, supplemented with explanations of local regulations, and re-verified for the applicable version.

What must be localised? Labels and instruction leaflets, post-market surveillance plans, clinical evaluation analyses related to local populations and epidemiology, and documents related to local agents and authorised representatives cannot be simply copied. They must be re-prepared according to the target country's requirements.

Local agent and certificate control issues deserve special attention. Many companies are not aware that the certificate owner may be an overseas agent; if the partnership breaks down, it will directly affect the renewal and variation of the registration certificate. Companies should ensure that control of the certificate or registration certificate is in their own hands, and sign clear contracts with qualified local agents that define the obligations for cooperation during variations and renewals.

For multi-country registration, companies should build a unified 'system evidence core package' and a 'difference matrix.' By using one set of master technical files plus a country-specific parameter table, the differences in quality system certificate requirements across markets can be managed centrally, significantly reducing redundant documentation and amendment risks. When inconsistencies arise, the preferred approach is to resolve them through supplementary evidence and expansion of the certification scope rather than complete recertification, saving time and cost.

In the long term, companies should establish an internal mechanism that links the quality system with registration, so that design changes and production address changes are reflected in system certificates and registration dossiers in a timely manner, fundamentally reducing inconsistency risks.

Frequently Asked Questions

Is recertification mandatory when quality system certificates are inconsistent?

Not necessarily. If the discrepancy is only a minor difference in standard version or scope description, and the certificate issuer is an internationally recognised body, it can be resolved by adding a difference declaration, providing audit records, or requesting a clarification letter from the certification body. If the target country does not recognise the existing certificate or the scope clearly does not cover the product, a scope expansion audit or recertification may be required.

Can a CE certificate be submitted as quality system evidence?

A CE certificate is usually based on ISO 13485, but some target countries do not directly accept a CE certificate as quality system evidence. A CE certificate primarily demonstrates that the product meets EU regulatory requirements, while the target country's regulatory authority may require a separate ISO 13485 certificate or a local GMP audit. Therefore, the decision depends on the specific country's requirements and cannot be directly substituted.

How should an inconsistency in the quality system certificate be handled after a production address change?

A production address change is a significant change. The company should apply to the certification body for an address change on the certificate and complete a change declaration with the target country's regulatory authority. If the change involves a new manufacturing site, a new on-site audit may be required. Before approval, the production address in the registration dossier should remain consistent with the latest valid certificate to avoid amendment due to address mismatch.

Continued Reading / Related Topics

Previous: What should be prepared before renewal of overseas registration for rehabilitation devices?

Next: How to determine the product classification for overseas registration of implantable products?

Recommended:

• How to conduct post-market surveillance for overseas registration of rehabilitation devices?
• When should a registration change be declared for overseas registration of rehabilitation devices?
• What should be prepared before renewal of overseas registration for rehabilitation devices?
• How to determine the product classification for overseas registration of implantable products?
• How to organise the technical documentation for overseas registration of implantable products?
• How to divide the responsibilities of an authorised representative for overseas registration of imaging equipment?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory agencies, international organisations, standards organisations, and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal opinions of the target country's regulatory authority.